NCT00352131 (Clinical Trial/ IMGN242 / HuC242-DM4)

Study Title
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors (NCT00352131)

Trial Description
Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242 (IMGN242), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

This phase I trial is studying the side effects and best dose of maytansinoid DM4-conjugated humanized monoclonal antibody huC242 in treating patients with solid tumors that cannot be removed by surgery or have spread to other parts of the body.

This trial is sponsored by ImmunoGen, Inc. [1]

Study Data

  • Condition: Non-colorectal Cancer, Pancreatic Cancer
  • Interventions:
    • Drugs used in this trial
      • HuC242-DM4 (IMGN242)
  • Phase: I
  • Estimated Enrollment: 50
  • Start: February 2005
  • Completion: December 2009
  • Last verified: March 2010

Study Schematic 

(Coming soon)


Last Editorial review: July 8, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.